Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines

Anti-Cancer Drugs

Volumn 18, Issue 3, 2007, Pages 245-254

  Hartmann, Jörg T ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Chemotherapy; Refractory; Soft tissue sarcoma

Indexed keywords

1,11 DICHLORO 6 (2 DIETHYLAMINOETHYL) 12,13 DIHYDRO 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 (4 O METHYLGLUCOSIDE); 4 DEDIMETHYLAMINOSANCYCLINE; ANN 107; ANTHRACYCLINE DERIVATIVE; AURISTATIN PE; BENDAMUSTINE; BIRICODAR; BORTEZOMIB; BROSTALLICIN; DACARBAZINE; DASATINIB; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EVEROLIMUS; EXATECAN; GEFITINIB; GEMCITABINE; GPX 100; HSPPC 96; IFOSFAMIDE; IMATINIB; IRINOTECAN; IXABEPILONE; MIDOSTAURIN; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; NAVELBINE; NSC 639966; PACLITAXEL; PERIFOSINE; PHOSPHOTRANSFERASE INHIBITOR; RALTITREXED; RUBITECAN; SORAFENIB; TEMOZOLOMIDE; TOPOTECAN; TRABECTEDIN; TROFOSFAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ADD ON THERAPY; ALOPECIA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CHEMICAL CYSTITIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DEHYDRATION; DESMOPLASTIC SMALL ROUND CELL TUMOR; DIARRHEA; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FATALITY; DRUG TARGETING; DRUG TREATMENT FAILURE; EWING SARCOMA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TOXICITY; HUMAN; ILEUS; KAPOSI SARCOMA; LEUKOPENIA; LIPOSARCOMA; LIVER TOXICITY; LOW DRUG DOSE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTEIN TARGETING; RECOMMENDED DRUG DOSE; REVIEW; RHABDOMYOLYSIS; RHABDOMYOSARCOMA; SEPSIS; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; SYSTEMIC THERAPY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ALKYLATING AGENTS; ANIMALS; ANTHRACYCLINES; ANTIMETABOLITES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DNA TOPOISOMERASES, TYPE I; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SARCOMA; TAXOIDS; THYMIDYLATE SYNTHASE;

EID: 33846705266     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3280124e41     Document Type: Review

References (91)

1. Bauer S, Hartmann JT. Locally advanced and metastatic sarcoma (adult type) including gastrointestinal stromal tumors (GIST). Crit Rev Oncol Hematol 2006; 60:112-130.
2. Patel SR, Chu P, Vadhan-Raj S. Differential responsiveness of leiomyosarcoma (leio) arising at different sites to doxorubicin-based chemotherapy. Proc Am Assoc Cancer Res 1997; 38:7.
3. Bertuzzi A, Castagna L, Nozza A, Quagliuolo V, Siracusano L, Balzarotti M, et al. High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study. J Clin Oncol 2002; 20:2181-2188.
4. Kushner BH, LaQuaglia MP, Wollner N, Meyers PA, Lindsley KL, Ghavimi F, et al. Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J Clin Oncol 1996; 14:1526-1531.
5. Borden EC, Amato DA, Rosenbaum C, Enterline HT, Shiraki MJ, Creech RH, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987; 5:840-850.
6. Lopez M, Vici P, Di Lauro L, Carpano S. Increasing single epirubicin doses in advanced soft tissue sarcomas. J Clin Oncol 2002; 20:1329-1334.
7. 2 in advanced soft tissue sarcoma: a trial of the EORTC Early Clinical Studies Group. Eur J Cancer 1998; 34:422-423.
8. Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 2003; CD003293.
9. Bokemeyer C, Franzke A, Hartmann JT, Schober C, Arseniev L, Metzner B, et al. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997; 80:1221-1227.
10. Frustaci S, Buonadonna A, Galligioni E, Favaro D, De Paoli A, Lo RG, et al. Increasing 4′-epidoxorubicin and fixed ifosfamide doses plus granulocytemacrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study. J Clin Oncol 1997; 15:1418-1426.
11. Reichardt P, Tilgner J, Hohenberger P, Dorken B. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol 1998; 16:1438-1443.
12. Steward WP, Verweij J, Somers R, Spooner D, Kerbrat P, Clavel M, et al. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1993; 11:15-21.
13. Patel SR, Vadhan-Raj S, Burgess MA, Plager C, Papadopolous N, Jenkins J, Benjamin RS. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 1998; 21:317-321.
14. Benjamin RS, Legha SS, Patel SR, Nicaise C. Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. Cancer Chemother Pharmacol 1993; 31 (Suppl 2):S174-S179.
15. Gottlieb JA, Benjamin RS, Baker LH, O'Bryan RM, Sinkovics JG, Hoogstraten B, et al. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep 1976; 60:199-203.
16. Spath-Schwalbe E, Genvresse I, Koschuth A, Dietzmann A, Grunewald R, Possinger K. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs 2000; 11:325-329.
17. Svancarova L, Blay JY, Judson IR, Van Hoesel QG, Van Oosterom AT, le Cesne A, et al. Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002; 38:556-559.
18. Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, Galanis E. Phase II trial of gemcitabine in advanced sarcomas. Cancer 2002; 94:3225-3229.
19. Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001; 19:3483-3489.
20. Okuno S, Ryan LM, Edmonson JH, Priebat DA, Blum RH. Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group. Cancer 2003; 97:1969-1973.
21. Van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002; 38:543-549.
22. Hartmann JT, Oechsle K, Huober J, Jakob A, Azemar M, Horger M, et al. An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Invest New Drugs 2005.
23. Amodio A, Carpano S, Manfredi C, Del Monte G, Di Lauro L, Gionfra T, et al. Gemcitabine in advanced stage soft tissue sarcoma: a phase II study. Clin Ter 1999; 150:17-20.
24. Blumgart LH, Espat N, Fong Y, Jarnagin WR. Limited activity and acceptable toxicity of gemcitabine in a phase II study of patients with advanced sarcomas: a mayo cancer center study. Proc Am Soc Clin Oncol 2000; 19 [abstr 50].
25. Fata F, O'Reilly E, Ilson D, Pfister D, Leffel D, Kelsen DP, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999; 86:2034-2037.
26. Balcerzak SP, Benedetti J, Weiss GR, Natale RB. A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A Southwest Oncology Group study. Cancer 1995; 76:2248-2252.
27. Gallup DG, Blessing JA, Andersen W, Morgan MA. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 2003; 89:48-51.
28. Van Hoesel QG, Verweij J, Catimel G, Clavel M, Kerbrat P, Van Oosterom AT, et al. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 1994; 5:539-542.
29. Kostler WJ, Brodowicz T, Attems Y, Hejna M, Tomek S, Amann G, et al. Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. Ann Oncol 2001; 12:1281-1288.
30. Edmonson JH, Ebbert LP, Nascimento AG, Jung SH, McGaw H, Gerstner JB. Phase II study of docetaxel in advanced soft tissue sarcomas. Am J Clin Oncol 1996; 19:574-576.
31. Verweij J, Lee SM, Ruka W, Buesa J, Coleman R, Van Hoessel R, et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000; 18:2081-2086.
32. Okuno S, Geyer SM, Maples WJ, Stewart J, Fitch TR, Fracasso PM, et al. Phase 2 study of epothilone B analog (BMS-247550) in soft tissue sarcomas: an interim report. Proc Am Soc Clin Oncol 2002; 21:412a [abstract 1645].
33. Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004; 22:890-899.
34. Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004; 22:1480-1490.
35. Hartmann JT, Oechsle K, Mayer F, Kanz L, Bokemeyer C. Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas. Anticancer Res 2003; 23 (2C):1899-1901.
36. Kollmannsberger C, Brugger W, Hartmann JT, Maurer F, Bohm P, Kanz L, Bokemeyer C. Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma. Anticancer Drugs 1999; 10:453-456.
37. Blomqvist C, Wiklund T, Pajunen M, Virolainen M, Elomaa I. Oral trofosfamide: an active drug in the treatment of soft-tissue sarcoma. Cancer Chemother Pharmacol 1995; 36:263-265.
38. Woll PJ, Judson I, Lee SM, Rodenhuis S, Nielsen OS, Buesa JM, et al. Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1999; 35:410-412.
39. Trent JC, Beach J, Burgess MA, Papadopolous N, Chen LL, Benjamin RS, Patel SR. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 2003; 98:2693-2699.
40. Hartmann J, Schleicher J, Huober J, Denzlinger C, Kaefer G, Gruenwald V, et al. Bendamustine hydrochloride as salvage treatment for patients (pts) with pretreated adult type soft tissue sarcoma (STS): a non-comparative phase II study (AIO-01). Onkologie 2005; 28 (Suppl 3):55 [abstr 154].
41. Budd GT, Rankin C, Hutchins LF, Wong L, Petruska PJ, Antman K. Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study. Southwest Oncology Group. Invest New Drugs 2002; 20:129-132.
42. Reichardt P, Oechsle K, Pink D, Bokemeyer C, Schneller F, Issels R, et al. An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma. Invest New Drugs 2003; 21:481-486.
43. Saylors RL III, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001; 19:3463-3469.
44. Hosono A, Makimoto A, Kawamoto H, Sakiyama M, Matsubara H, Yokoyama R, et al. A retrospective analysis in safety and efficacy of protracted administration of irinotecan for patients with small round cell sarcomas relapsed after stem cell transplantation (SCT). Proc Am Soc Clin Oncol 2003; 22:813 [abstr 3269].
45. Pappo AS, Lyden E, Breitfeld PP, Houghton P, Parham D, Donaldson SS, et al. Irinotecan (CPT-11) is active against pediatric rhabdomyosarcoma (RMS): a phase II window trial from the Soft Tissue Sarcoma Committee (STS) of the Children's Oncology Group (COG). Proc Am Soc Clin Oncol 2002; 21:393 [abstr 1570].
46. De Angelo D, Naujoks R, Manola J, Harmon D, Demetri GD. Phase II Study of Irinotecan (CPT-11) in Relapsed or Refractory Soft Tissue Sarcoma (STS). Proc Am Soc Clin Oncol 2000; 19 [abstr 2186].
47. Patel SR, Beach J, Papadopoulos N, Burgess MA, Trent J, Jenkins J, Benjamin RS. Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas. Cancer 2003; 97:2848-2852.
48. Pink D, Reichardt P, Nielsen OS, Bauer S, Hartmann JT, Schoeffski P, et al. Exatecan (DX-8951f), a new topoisomerase I-inhibitor, is inactive in heavily pretreated patients (pts.) with advanced soft tissue sarcoma (STS): a phase II-study of the EORTC Soft Tissue and Bone Sarcoma Group. Proc Am Soc Clin Oncol 2005; 24 [abstr 9058].
49. Fidias P, Demetri GD, Harmon D. Navelbine shows activity in previously treated sarcoma patients: phase II results from MGH/DANA farber/partner's cancercare study (Meeting abstract). Proc Am Soc Clin Oncol 1998; 17:513a [abstr 1977].
50. Blay JY, Judson I, Rodenhuis S, Hermans C, Smith M, Van Glabbeke M, Verweij J. Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens. Anticancer Drugs 1999; 10:873-877.
51. Maki R, Kraft A, Demetri GD, Siegel E, Hirst C, Connors S, et al. A phase II multicenter study of proteasome inhibitor PS-341 (LDP-341, bortezomib) for untreated recurrent or metastatic soft tissue sarcoma (STS); CTEP study 1757. Proc Am Soc Clin Oncol 2003; 22:819 [abstr 3291].
52. Bramwell VH, Morris D, Ernst DS, Hings I, Blackstein M, Venner PM, et al. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Clin Cancer Res 2002; 8:383-393.
53. Bailey H, Mahoney M, Okuno S, Ettinger DS, Maples WJ, Fracasso PM, Erlichman C. Tolerability and limited activity of perifosine in patients with advanced soft tissue sarcoma (STS): a multi-center phase 2 consortium (P2C) study. Eur J Cancer 2004; 2 (Suppl):113 [abstr 377].
54. D'Adamo DR, Anderson SE, Albritton K, Yamada J, Riedel E, Scheu K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005; 23:7135-7142.
55. Pacey SC, Ratain MJ, O'Dwyer P, Xiong H, Patnaik A, Eisen T, et al. Phase II antitumor activity of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in patients with sarcoma enrolled in a randomized discontinuation study. Eur J Cancer 2004; 2 (Suppl):114 [abstr 382].
56. Demetri GD, Van Oosterom AT, Blackstein M, Garrett C, Shah M, Heinrich M, et al. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST. Proc Am Soc Clin Oncol 2005; 24 [abstr 4000].
57. Delaloge S, Yovine A, Taamma A, Riofrio M, Brain E, Raymond E, et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. J Clin Oncol 2001; 19:1248-1255.
58. Demetri GD. ET-743: the US experience in sarcomas of soft tissues. Anticancer Drugs 2002; 13 (Suppl 1):S7-S9.
59. Puchalski TA, Ryan DP, Garcia-Carbonero R, Demetri GD, Butkiewicz L, Harmon D, et al. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol 2002; 50:309-319.
60. Takahashi N, Li WW, Banerjee D, Scotto KW, Bertino JR. Sequencedependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res 2001; 7:3251-3257.
61. Leahy MG, Blay JY, le Cesne A, Verweij J, Duffaud F, Hogendoorn PC, et al. EORTC 62011: phase II trial of brostallicin for soft tissue sarcoma. CTOS 9th Annual Meeting 2003; 46 [abstr 94].
62. Casanova M, Ferrari A, Spreafico F, Terenziani M, Massimino M, Luksch R, et al. Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma. Cancer 2002; 94:3263-3268.
63. Stevens MF, Hickman JA, Stone R, Gibson NW, Baig GU, Lunt E, Newton CG. Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2- chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one , a novel broad-spectrum antitumor agent. J Med Chem 1984; 27:196-201.
64. Tsang LL, Quarterman CP, Gescher A, Slack JA. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide. Cancer Chemother Pharmacol 1991; 27:342-346.
65. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3- methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987; 47:5846-5852.
66. Wall ME, Wani MC, Natschke SM, Nicholas AW. Plant antitumor agents. 22. Isolation of 11-hydroxycamptothecin from Camptotheca acuminata Decne: total synthesis and biological activity. J Med Chem 1986; 29:1553-1555.
67. Kharbanda S, Rubin E, Gunji H, Hinz H, Giovanella B, Pantazis P, Kufe D. Camptothecin and its derivatives induce expression of the c-jun protooncogene in human myeloid leukemia cells. Cancer Res 1991; 51:6636-6642.
68. Natelson EA, Giovanella BC, Verschraegen CF, Fehir KM, De Ipolyi PD, Harris N, Stehlin JS. Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann N Y Acad Sci 1996; 803:224-230.
69. O'Reilly S, Rowinsky EK, Slichenmyer W, Donehower RC, Forastiere AA, Ettinger DS, et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 1996; 14:3062-3073.
70. Bramwell VH, Eisenhauer EA, Blackstein M, Boos G, Knowling M, Jolivet J, Bogues W. Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcoma. Ann Oncol 1995; 6:847-849.
71. Judson I, Radford JA, Harris M, Blay JY, Van Hoesel Q, le Cesne A, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001; 37:870-877.
72. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002; 20:2824-2831.
73. Pivot X, Chevreau C, Cupissol D, Lortholary A, Bui NB, Eymard JC, et al. Phase II trial of paclitaxel-epirubicin in patients with recurrent soft-tissue sarcoma. Am J Clin Oncol 2002; 25:561-564.
74. Raney RB, Anderson JR, Barr FG, Donaldson SS, Pappo AS, Qualman SJ, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 2001; 23:215-220.
75. Casanova M, Ferrari A, Bisogno G, Merks JH, De Salvo GL, Meazza C, et al. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer 2004; 101:1664-1671.
76. Whelan JS, McTiernan A, Kakouri E, Kilby A. Carboplatin-based chemotherapy for refractory and recurrent Ewing's tumours. Pediatr Blood Cancer 2004; 43:237-242.
77. Van Winkle P, Angiolillo A, Krailo M, Cheung YK, Anderson B, Davenport V, et al. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. Pediatr Blood Cancer 2005; 44:338-347.
78. Tolcher AW, Eckhardt SG, Kuhn J, Hammond L, Weiss G, Rizzo J, et al. Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. J Clin Oncol 2001; 19:2937-2947.
79. Papadopoulos K, Chu Q, Syed S, Curtright J, Schwartz G, Mita M, et al. A two-stage phase II study of the matrix metalloproteinase inhibitor (MMPI). Col-Co3 in patients with advanced soft tissue sarcoma (ASTS)-report of Stage I data. Eur J Cancer 2004; 2 (Suppl):45 [abstr 140].
80. Arbiser JL, Larsson H, Claesson-Welsh L, Bai X, LaMontagne K, Weiss SW, et al. Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo. Am J Pathol 2000; 156:1469-1476.
81. Sirvent N, Maire G, Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer 2003; 37:1-19.
82. McArthur GA, Demetri GD, Van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005; 23:866-873.
83. Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006; 24:1195-1203.
84. Casali PG, Messina A, Stacchiotti S, Tamborini E, Crippa F, Gronchi A, et al. Imatinib mesylate in chordoma. Cancer 2004; 101:2086-2097.
85. Koon HB, Bubley GJ, Pantanowitz L, Masiello D, Smith B, Crosby K, et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol 2005; 23:982-989.
86. Verweij J, Van Oosterom A, Blay JY, Judson I, Rodenhuis S, Van der GW, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other softtissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003; 39:2006-2011.
87. Van Oosterom A, Reichardt P, Blay JY, Dumez H, Fletcher JA, Debiec-Rychter M, et al. A phase I/II trial of the oral mTOR-inhibitor Everolimus (E) and Imatinib Mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: study update. Proc Am Soc Clin Oncol 2005; 24 [abstr 9033].
88. Reichardt P, Pink D, Lindner T, Heinrich MC, Cohen PS, Wang Y, et al. A phase I/II trial of the oral PKC-inhibitor PKC412 (PKC) in combination with imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM. Proc Am Soc Clin Oncol 2005; 24 [abstr 3016].
89. Debrock G, Vanhentenrijk V, Sciot R, Debiec-Rychter M, Oyen R, Van Oosterom A. A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer 2003; 89:1409-1412.
90. Li W, Fan J, Bertino JR. Selective sensitization of retinoblastoma proteindeficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity. Cancer Res 2001; 61:2579-2582.
91. Tomek S, Koestler W, Horak P, Grunt T, Brodowicz T, Pribill I, et al. Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines. Eur J Cancer 2003; 39:1318-1329.